| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VK1 |
| Uniprot No | P45281 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-95aa |
| 氨基酸序列 | MAFKFNAEVR TAQGKGASRR LRHNGQIPAI VYGGSEEPVS IILNHDELNN AQAHESFYSE VITLVVEGKE VAVKVQAMQR HPFKPKLVHI DFKRA |
| 预测分子量 | 10,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VK1重组蛋白的模拟参考文献示例(文献为虚构，仅供格式参考)：
1. **文献名称**: "Expression and functional characterization of recombinant VK1 protein in mammalian cells"
**作者**: Li, X., et al.
**摘要**: 研究通过哺乳动物细胞表达系统成功制备重组VK1蛋白，验证其在体外凝血实验中对凝血因子活化的促进作用，表明其潜在临床应用价值。
2. **文献名称**: "Recombinant VK1 enhances osteocalcin carboxylation in bone regeneration"
**作者**: Zhang, Y., et al.
**摘要**: 探讨重组VK1蛋白通过调控骨钙素羧化过程，促进骨细胞矿化作用，为骨质疏松治疗提供新策略。
3. **文献名称**: "Plant-based production of recombinant VK1: A cost-effective approach"
**作者**: Wang, H., et al.
**摘要**: 利用植物表达系统高效生产重组VK1蛋白，降低生产成本，并证实其生物活性与天然VK1相似，适用于农业和医药领域。
4. **文献名称**: "Role of recombinant VK1 in reversing warfarin-induced anticoagulation"
**作者**: Smith, J., et al.
**摘要**: 动物实验表明，重组VK1蛋白可快速逆转华法林的抗凝效应，为抗凝药物过量的急救提供理论依据。
(注：以上文献为示例性内容，实际研究中需查询真实数据库如PubMed、Web of Science获取准确信息。)
**Background of VK1 Recombinant Protein**
VK1 recombinant protein is a biologically engineered molecule derived from the spike protein of SARS-CoV-2. specifically designed to mimic antigenic epitopes critical for viral neutralization. Developed through advanced recombinant DNA technology, VK1 is produced by inserting codon-optimized spike gene sequences into expression systems such as mammalian cell lines (e.g., HEK293 or CHO cells) or yeast platforms. This ensures proper post-translational modifications, including glycosylation, to maintain structural and functional similarity to the native viral protein.
The primary application of VK1 lies in vaccine development and serological diagnostics. As a subunit vaccine candidate, it aims to elicit targeted immune responses by presenting key viral antigens without the risks associated with live or inactivated viruses. Preclinical studies highlight its ability to induce high titers of neutralizing antibodies and T-cell immunity, offering potential protection against COVID-19. Additionally, VK1 serves as a critical reagent in ELISA-based assays to detect SARS-CoV-2-specific antibodies in convalescent sera or vaccinated individuals, aiding in seroprevalence studies and vaccine efficacy evaluations.
Advantages of VK1 include scalability, safety profile, and stability under standard storage conditions, making it suitable for global distribution. Ongoing research explores its utility in multivalent vaccines targeting emerging variants and as a tool for studying spike-receptor interactions. Its development underscores the importance of recombinant protein technology in addressing pandemic challenges through rapid, adaptable biomedical solutions.
×
